Ionis Pharmaceuticals, Inc.’s Post

Alkem signs non-exclusive patent license agreement with Takeda to commercialise Vonoprazan in India Alkem Laboratories announced that it has signed a non-exclusive patent license agreement with Takeda Pharmaceutical Company to commercialise Vonoprazan in India, under the brand name “Vonzai” as oral tablets, in 20 mg and 10 mg strengths. Vonoprazan is a first-in-class potassium-competitive acid blocker (P-CAB), discovered and developed by Takeda. Vonoprazan has a novel mechanism of action, whereby it inhibits H+, K+-ATPase activities in a reversible and potassium-competitive manner, eliciting gastric acid suppression with high serum gastrin concentration. In India, Vonoprazan is indicated in the treatment of reflux esophagitis (RE) and other indications.

📣FEBRUARY'S FDA ROUNDUP - EYP-1901: Wet Age-Related Macular Degeneration US-based pharmaceutical company EyePoint Pharmaceuticals has reported positive topline data from the Phase II DAVIO 2 clinical trial of EYP-1901, which is an investigational therapy being trialed for the treatment of wet age-related macular degeneration (wet AMD).3 According to the report, “EYP-1901 also demonstrated a favourable safety profile without any treatment-associated ocular or systemic serious adverse events being reported.”3 EyePoint Pharmaceuticals president and CEO Jay Duker said: “The 32-week topline DAVIO 2 data strongly supports our planned Phase III noninferiority design, consistent with the FDA’s recent guidance for wet AMD clinical trials.” 3 ⭐The FDA Roundup is bringing you up to speed with the latest announcements and approvals in #Ophthalmology. Read here ➡️: https://brnw.ch/21wHc6V #DAVIO2 #EYP1901 #WetAMD #wAMD #AgeRelatedMacularDegeneration #Ophthalmologist #ClinicalTrial #EyeHealth

📢 We are thrilled to announce a significant milestone in our mission to improve the lives of patients suffering from Osteoarthritis.   Our partner, Hansoh Pharma (Jiangsu Hansoh Pharmaceutical Group Co., Ltd.), has successfully initiated the clinical trial for KioMedine-vs-one in China. This achievement marks a crucial step towards bringing our innovative treatment to over 100 million Osteoarthritis patients in the region.   We extend our gratitude to the dedicated teams at KiOmed Pharma and Hansoh Pharma for their work in reaching this pivotal stage. 👏   🔗 For more details on this development and its implications for Osteoarthritis treatment in China, please read our full press release: https://lnkd.in/eyxm8Yf5   #HealthTech #BiotechInnovation #ClinicalResearch #OsteoarthritisTreatment #ClinicalTrials #KiOmedPharma #Chitosan

JT and Torii Pharmaceutical Co., Ltd. announced the initial results of a Phase 3 comparative study relative to pediatric patients with atopic dermatitis in Japan treated with JTE-061(tapinarof). We will aim to submit a manufacturing and marketing application for JTE-061 cream in Japan, based on the results of this and other clinical studies. For detailed results, please refer to the press release: https://lnkd.in/g2_9jhfi #JT #Torii Pharmaceutical #Pharma #tapinarof   小児アトピー性皮膚炎患者を対象とした現在開発中のJTE-061(tapinarof)について、日本国内で実施中の第Ⅲ相臨床試験（比較試験）の速報結果を得ました。 今後、本試験の成績等をもとに、日本国内における製造販売承認申請を目指します。 詳細な速報結果については、プレスリリースをご覧ください: https://lnkd.in/gt2KMrSX

Otsuka President and CEO Tarek Rabah joined last week's Forbes Healthcare Summit panel, Fast Forward: Innovations in Treating Disease—and People. This year's Summit brought together the world's most influential healthcare leaders to discuss optimizing the connected digital healthcare experience and building a better healthcare ecosystem. At Otsuka, we are dedicated to serving those with unmet medical needs and are proud to be at the forefront of research and development for new innovations intended for those living with complex diseases, including mental illness. Discover our commitment to health for every mind: https://bit.ly/3Vs7ah4

世界藥學生聯合會亞太區辦公處（IPSF APRO）工業藥學競賽 International Pharmaceutical Students Federation Asian Pacific Reginal Office (IPSF APRO) Industrial Skills Event(ISE) •The aim of this proposal is to gain support from healthcare professionals and pharmaceutical companies, guiding the way for further research, clinical trials, and the approval of the medication for weight loss purposes. •Collect and analyze GLP-1 Receptor Agonist(GLP-1 RAs) weight loss drug market from all aspects to evaluate its future development prospects. •Create a compelling marketing plan for Novo Nordisk's yet-to-be FDA-approved oral GLP-1 RA, Rybelsus, to strengthen its market positioning and increase acceptance among medical professionals.

Pharmaceutical Drug Delivery Market to Hit USD 2,546 Billion by 2029 | MarketsandMarkets™ https://lnkd.in/g4-FE7jB DELRAY BEACH, Fla., Sept. 17, 2024 /PRNewswire/ — The global pharmaceutical drug delivery market is set to grow from USD 1,949.4 billion in 2024 to USD 2,546.0 billion by 2029, with a CAGR of 5.5%. [...]

To my international network: Do you have a national pharmaceutical strategy in your country? Let me know in the comments! In Sweden, the first national pharmaceutical strategy was released in 2011 and has been revised three times. The current strategy, that the Swedish government has released, is valid between 2024-2026 and covers three focus areas: - availability of new and old medicines - pharmaceutical treatment and medicine handling - development of new medicines and clinical trials

Patent expirations have a significant impact on the pharmaceutical industry, particularly on the generic drug market. When a drug’s patent expires, other manufacturers can produce and market generic versions of the drug, leading to increased competition and lower prices. This article will explore the effects of patent expirations on generic drug markets, including the decrease in drug prices, the increase in generic competition, and the impact on pharmaceutical companies. https://lnkd.in/efQWAbt2

Over a decade ago, CMIC Group, one of Japan’s largest CROs, and MEDIPAL, a leading pharmaceutical wholesaler, united to establish OrphanPacific Inc. with a bold mission: accelerate the introduction of innovative medicines for rare diseases. Dive deeper into this transformative model and the dynamic partnership in our webinar, "Make the Impossible Possible: An Innovative Partnership for Market Entry in Japan." Watch the Recording: https://lnkd.in/dVt8xfe #JapanMarketEntry #PharmaConsulting